BACK

High gene expression levels of ARF6 are associated with the immune microenvironment and predict poor outcomes

Authors:

Natsuko Kawanishi, Yasmine Baca, Joanne Xiu, Hiroyuki Arai, Francesca Battaglin, Priya Jayachandran, Shivani Soni, Wu Zhang, Philip Agop Philip, Davendra Sohal, Mohd Khushman, Benjamin Adam Weinberg, Michael J. Hall, David J. Park, Anthony Frank Shields, A. Craig Lockhart, Wolfgang Michael Korn, Heinz-Josef Lenz, Emil Lou

Background: ADP-ribosylation factor 6 (ARF6) is a small GTPase in the RAS superfamily, which regulates membrane trafficking, remodeling and tumor progression. Preclinical study shows that TP53 and KRAS cooperatively activate the ARF6-AMAP1 pathway which serves as a link by which pancreatic driver mutations promote tumor invasion, PD-L1 dynamics and immune evasion properties in pancreatic ductal adenocarcinoma (PDAC). The clinical impact of ARF6 on cancer progression and prognosis remains unclear.

Download Publication